Market Place
Sourcing Support
Dupixent® Late-Breaking Phase 3 Data In Chronic Urticaria
24 Oct 2024 //
GLOBENEWSWIRE
Kymera Announces FDA Clearance Of IND For KT-621
09 Oct 2024 //
GLOBENEWSWIRE
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
28 Sep 2024 //
BIOSPACE
Dupixent Approved In U.S. As First Biologic For COPD
27 Sep 2024 //
GLOBENEWSWIRE
Dupixent Approved As First Biologic Medicine For COPD Patients
27 Sep 2024 //
GLOBENEWSWIRE
Kymera Presents KT-621 Preclinical Data At EADV Congress
25 Sep 2024 //
GLOBENEWSWIRE
DARZALEX based quadruplet regimen receives positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Dupixent Recommended for EU Approval by the CHMP
20 Sep 2024 //
GLOBENEWSWIRE
CHMP Backs Pfizer-BioNTech`s Omicron COVID-19 Vaccine
20 Sep 2024 //
GLOBENEWSWIRE
Dupixent Approved For Adolescents With Chronic Rhinosinusitis With Polyps
13 Sep 2024 //
GLOBENEWSWIRE
Dupixent Phase 3 Trial Shows Improvement In Chronic Spontaneous Urticaria
11 Sep 2024 //
GLOBENEWSWIRE
Sanofi And Regeneron Show Data For Dupixent In Hives After FDA Rejection
11 Sep 2024 //
FIERCE PHARMA
Dupixent 1st to Achieves Improvements In Bullous Pemphigoid Study
10 Sep 2024 //
GLOBENEWSWIRE
Connect reduces China workforce, mulls strategy for potential Dupixent rival
06 Sep 2024 //
FIERCE BIOTECH
Dupixent And Itepekimab Data At ERS Show Leadership In Respiratory Diseases
26 Aug 2024 //
GLOBENEWSWIRE
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
03 Jul 2024 //
PRESS RELEASE
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
26 Jun 2024 //
PRESS RELEASE
Dupixent® Positive Phase 3 Data in Children 1-11 with Eosinophilic Esophagitis
26 Jun 2024 //
GLOBENEWSWIRE
Dupixent Recommended For EU COPD Approval By CHMP
31 May 2024 //
PRESS RELEASE
Dupixent FDA Priority Review Update For COPD With Type 2 Inflammation
30 May 2024 //
PRESS RELEASE
J&J acquires experimental skin disorder drug for $1.25 billion
29 May 2024 //
BIOPHARMADIVE
Dupixent NOTUS COPD Phase 3 Data At ATS, NEJM
20 May 2024 //
GLOBENEWSWIRE
FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years
13 May 2024 //
PRESS RELEASE
Dupixent sBLA Priority Review For Adolescent CRSwNP
13 May 2024 //
GLOBENEWSWIRE
ASLAN On Eblasakimab Data In Atopic Dermatitis From TREK-DX Study
07 May 2024 //
GLOBENEWSWIRE
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
03 May 2024 //
FIERCE PHARMA
ASLAN KOL Panel on AD Treatment Options Post-Dupilumab
30 Apr 2024 //
GLOBENEWSWIRE
Regeneron, Sanofi tweak Dupixent message for latest asthma ads
29 Apr 2024 //
FIERCE PHARMA
Sanofi ATS Data Advances Potential Therapies in Respiratory Diseases
26 Apr 2024 //
PRESS RELEASE
Sanofi Q1 profit slips on generic competition, forex effects
25 Apr 2024 //
REUTERS
ASLAN`s Eblasakimab Positive Interim Atopic Dermatitis Data
22 Apr 2024 //
GLOBENEWSWIRE
Regeneron`s Dupixent (dupilumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Sanofi plans to launch 1 or 2 products in India every year
01 Apr 2024 //
ECONOMICTIMES
Dupixent sBLA Accepted for FDA Priority Review for Treatment of COPD
24 Feb 2024 //
PRESS RELEASE
FDA grants priority review for Dupixent in COPD
22 Feb 2024 //
ENDPTS
After FDA says no on Dupixent for hives disorder, Japan says yes
16 Feb 2024 //
FIERCE PHARMA
Japan first in the world to approve Dupixent® for CSU
15 Feb 2024 //
PRESS RELEASE
US FDA approves Dupixent to treat younger kids with esophageal condition
26 Jan 2024 //
PRESS RELEASE
Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.
25 Jan 2024 //
FDA
Dupixent Label Updated with Data Further Supporting Use in Atopic Dermatitis
16 Jan 2024 //
PRESS RELEASE
Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.
12 Jan 2024 //
FDA
Kymera doubles down on protein degraders for immunology
04 Jan 2024 //
ENDPTS
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
07 Dec 2023 //
REUTERS
Sanofi, Regeneron`s Dupixent scores again in second COPD trial
28 Nov 2023 //
FIERCE PHARMA
Regeneron expects key Dupixent COPD data this year
02 Nov 2023 //
ENDPTS
Dupixent Phase 3 Results show sustained efficacy in children with EoE
24 Oct 2023 //
PRESS RELEASE
FDA deals blow to Sanofi, Regeneron’s approval efforts for Dupixent in hives
21 Oct 2023 //
PRESS RELEASE
Dupixent sBLA for treatment of EoE accepted for FDA Priority Review
26 Sep 2023 //
GLOBENEWSWIRE
Sanofi lifts earnings outlook on new drug launches, Dupixent sales
27 Jul 2023 //
REUTERS
~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug
26 Jul 2023 //
PR NEWSWIRE
Regeneron`s Biologic Dupixent® (dupilumab) Receives Approval in the U.S.
14 Jul 2023 //
FDA
Dupixent is approved in India for moderate-to-severe atopic dermatitis
13 Jul 2023 //
INDIAN PHARMA POST
Sanofi pumps up Dupixent and other respiratory pipeline drugs
23 May 2023 //
FIERCE PHARMA
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS
21 May 2023 //
GLOBENEWSWIRE
Positive data from two Phase 3 Dupixent trials in prurigo nodularis published
08 May 2023 //
PRESS RELEASE
Dupixent now approved in Canada for children with severe atopic dermatitis
21 Apr 2023 //
PRESS RELEASE
Sanofi, Regeneron`s Dupixent tops expectations in first pivotal COPD study
24 Mar 2023 //
PRESS RELEASE
Sanofi`s Dupixent Gets EU Nod for Eczema in Young Kids
22 Mar 2023 //
NASDAQ
COPD trial data coming soon for Sanofi, Regneron’s Dupixent
20 Mar 2023 //
FIERCE PHARMA
Dupixent late-breaking data at AAD show improvements in atopic dermatitis
18 Mar 2023 //
GLOBENEWSWIRE
